IDEXX Laboratories stock holds Stifel Buy rating after Q2 earnings beat
Published on 09/18/2026 at 21:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
IDEXX Laboratories stock (ISIN US45168D1046) is trading around USD 506.48 on Nasdaq as of September 18, 2026, leaving the shares well below a reiterated analyst price target but supported by a recent earnings beat and guidance raise.
Stifel reiterates Buy rating and USD 675 target
According to Investing.com on September 18, 2026, Stifel has reaffirmed its Buy rating on IDEXX Laboratories stock and maintained a price target of USD 675.00 following a survey of veterinary practices.
In the same overview, Investing.com notes that IDEXX Laboratories stock is quoted at USD 506.48, close to its 52 week low of USD 500.61 and about 25 percent below its 52 week high of USD 770.00.
From an investor perspective, this means the stock trades at a significant discount of roughly USD 168.52 to Stifel's USD 675.00 price target as of September 18, 2026, while also sitting near the lower end of its one year trading range.
Q2 2026 results beat expectations and support guidance raise
In current fundamental terms, IDEXX Laboratories most recent quarterly results for the second quarter of 2026 provide the main earnings backdrop for the stock.
According to Investing.com Korea, IDEXX Laboratories reported adjusted earnings per share of USD 4.27 in the second quarter of 2026, clearly above Wall Street's consensus estimate of USD 3.96 per share.
The same report from Investing.com Korea states that IDEXX achieved revenue of USD 1.22 billion in Q2 2026, surpassing analyst expectations of USD 1.20 billion and representing a year over year increase of 10 percent.
Recurring diagnostics revenue showed organic growth of 10.3 percent in the quarter, according to Investing.com Korea, underlining the strength of IDEXX's core animal health testing business and providing a key driver for overall top line expansion.
Gross margin expanded to 64 percent in Q2 2026, up from the prior year period, supported by stronger recurring revenue and productivity improvements, as detailed by Investing.com Korea.
On the back of this performance, management raised full year guidance for 2026, with Investing.com Korea highlighting that the company increased its outlook after beating both earnings and revenue expectations in Q2 2026.
For investors, the combination of double digit revenue growth, a roughly USD 0.31 per share earnings beat versus consensus and a 64 percent gross margin in the latest quarter provides a quantitative basis for the premium valuation and for Stifel's relatively high USD 675 price target.
CoVet acquisition and product expansion strengthen diagnostics ecosystem
Beyond the headline numbers, IDEXX Laboratories has also been active on the strategic front in 2026, expanding its diagnostic and software offerings to reinforce long term growth.
As Zacks reported on September 18, 2026, IDEXX Laboratories recently acquired CoVetAI Inc., a provider of AI native ambient listening and clinical workflow software designed for veterinary practices.
According to the same article from Zacks, the CoVet acquisition supports IDEXX's strategy of using software and artificial intelligence as enablers of diagnostic insights, workflow efficiency and veterinary practice performance, although the financial terms of the deal were not disclosed.
Following the announcement of the CoVet acquisition, IDEXX Laboratories stock edged up 0.6 percent to close at USD 513.62 on Nasdaq on the previous trading day referenced in the article, as cited by Zacks.
The same Zacks note also mentions that IDEXX has launched the Catalyst proBNP test, described as the first dual species, in clinic test for NT proBNP in its portfolio, which expands the company's cardiac diagnostics capabilities across point of care and reference laboratory channels.
These developments in software and cardiac testing add qualitative support to the strong quantitative trends in recurring diagnostics revenue reported for Q2 2026 and help explain why Stifel and other observers see scope for further growth in IDEXX's animal health franchise.
Momentum and valuation context for IDEXX Laboratories stock
Despite solid fundamentals and strategic moves, IDEXX Laboratories stock has experienced weaker momentum in 2026.
According to MSN, IDEXX Laboratories carries a Momentum Grade of D+ with a year to date performance of minus 24.08 percent among large and mega cap United States healthcare stocks.
This negative 24.08 percent year to date move contrasts with the company's 10 percent year over year revenue growth and margin expansion in Q2 2026, suggesting a disconnect between price action and operating performance that medium term investors may scrutinize.
At the same time, the valuation discussion is shaped by free cash flow: a recent analysis from Yahoo Finance on September 18, 2026 notes that IDEXX's latest twelve month free cash flow stands around USD 1.2 billion, with model projections assuming continued growth into the early 2030s.
The same Yahoo Finance analysis argues that, based on the discounted cash flow assumptions used, IDEXX Laboratories stock currently trades below estimated fair value, providing one quantitative argument for investors who see upside potential despite the recent share price weakness.
Stock level near 52 week low and trading metrics
Recent price data underline the challenging technical picture for IDEXX Laboratories stock even as fundamentals remain robust.
According to the analyst overview from Investing.com, IDEXX Laboratories stock is quoted at USD 506.48 as of the latest trading snapshot, close to a 52 week low of USD 500.61 and roughly 25 percent below a 52 week high of USD 770.00.
In addition, the same table shows IDEXX Laboratories with a post market indication of USD 506.00, reflecting a marginal change of minus 0.09 percent from the regular session level, as indicated in an equity overview that includes IDEXX among United States transport and logistics peers on Seeking Alpha.
Given the illustrative market capitalization of around USD 40 billion at recent prices cited in a prior Nasdaq based commentary on September 18, 2026, this price range positions IDEXX firmly among large cap healthcare names, but the fall from the 52 week high indicates that the shares have already undergone a meaningful de rating compared with earlier in the year.
Closing view: price level and investor takeaway
As of September 18, 2026, IDEXX Laboratories stock trades on Nasdaq at approximately USD 506.48, near the lower end of its 52 week range of USD 500.61 to USD 770.00, and around USD 168.52 below Stifel's reiterated USD 675.00 price target.
For investors, the key numbers now are the 10 percent year over year revenue growth to USD 1.22 billion, the USD 4.27 adjusted earnings per share in Q2 2026 versus a USD 3.96 consensus, and the 64 percent gross margin, which, together with a roughly USD 1.2 billion trailing twelve month free cash flow, frame the debate on whether the current price level represents an opportunity or simply reflects the D+ momentum grade and negative 24.08 percent year to date performance.
IDEXX Laboratories stock - key data
- Company: IDEXX Laboratories, Inc.
- ISIN: US45168D1046
- Ticker: IDXX
- Trading venue: Nasdaq
- Price (as of September 18, 2026): 506.48 USD
- Market capitalization: 40,000,000,000 USD (as of September 18, 2026)
- Sector / Industry: Health Care / Animal Diagnostics
- Index membership: S&P 500
